Attovia Therapeutics

ATTO · Nasdaq · United States

Share price · ATTO

$15.53-7.71 (-33.18%) 3M

close as of 2026-11-18 · 24h delayed · vol 337K (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ATTO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

No unusual moves in the past 12 months.

Share of unusual movement by asset

For each asset, the share of ATTO's own-move activity since 6 Aug 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
ATTO-1310
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—89%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
IL-31Biologic (subtype unspecified)
Atopic Dermatitis

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-12-02 · Fiscal period ending 2026-09-30
What to watch
2028 (1)
August 2028 (1)
ATTO-1310Phase 2Chronic Pruritus of Unknown Origin
Est. primary completion 2028-08-30 · NCT07833306 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$20M$116M+ $281M short-term inv.$22M-$26M operating cash flowreport ↗
View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.5M$19M$33M+ $82M short-term inv.$21Mreport ↗
2025-Q3$0.4M$12M$50M$14M-$15M operating cash flowreport ↗
2025-Q2$0$14M$43M$14Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$41M+ $112M short-term inv.—report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$31M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 13 purchases ($72.9M), 92 sales ($9.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-06GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% OwnerConversion1,957,134——Form 4
2026-08-06WALSH COLIN · directorConversion1,957,134——Form 4
2026-08-06GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% OwnerConversion478,498——Form 4
2026-08-06WALSH COLIN · directorConversion478,498——Form 4
2026-08-06GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% OwnerOpen-market purchase500,000$17.00$8.5MForm 4
2026-08-06WALSH COLIN · directorOpen-market purchase500,000$17.00$8.5MForm 4
2026-08-06GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% OwnerConversion (derivative)18,181,830——Form 4
2026-08-06WALSH COLIN · directorConversion (derivative)18,181,830——Form 4